Image

Cardiac Power Output in Cardiogenic Shock Patients

Recruiting
18 years of age
Both
Phase N/A

Powered by AI

Overview

The main purpose of this study is to determine whether differences in myocardial reserve predict clinical outcomes for heart failure patients.

Description

This study is designed as a prospective, observational, crossover study to assess the feasibility of using differences in invasive hemodynamics of cardiac function, representing myocardial reserve, to predict clinical outcomes for heart failure patients. Patients with heart failure referred for right heart catheterization (RHC) by the advanced heart failure team as part of 1) evaluation for advanced heart failure therapies, including left ventricular assist device (LVAD), orthotopic heart transplant (OHT), temporary or long-term inotrope therapy, or counter-pulsation (temporary intra-aortic balloon pump (IABP) or long-term with NuPulse device), 2) for accurate assessment of invasive hemodynamics due to worsening clinical status, 3) assessment of myocardial recovery for consideration of LVAD or NuPulse decommissioning or removal or mechanical circulatory support removal, or 4) accurate assessment of cardiac function in patients with reduced LVEF prior to valve replacement for aortic insufficiency (AI) or mitral regurgitation (MR).

Eligibility

Inclusion Criteria:

  1. LVEF ≤ 35%
  2. Referred for RHC for:
    1. Evaluation for advanced heart failure therapies, including LVAD, OHT, temporary or long-term inotrope therapy, or counter-pulsation (temporary or long-term with NuPulse device OR
    2. Accurate assessment of invasive hemodynamics due to worsening clinical status, OR
    3. Assessment of myocardial recovery for consideration of LVAD or counter-pulsation (temporary IABP or long-term with NuPulse device) decommissioning or removal OR
    4. Assessment of cardiac function and valvular abnormalities prior to planned valvular surgery for MR or AI
  3. Estimated glomerular filtration rate (eGFR) ≥ 30 ml/min/1.73 m2
  4. Age ≥ 18 years-old
  5. Intent for admission based on RHC data

Exclusion Criteria:

  1. eGFR < 30 ml/min/1.73 m2
  2. Severe, non-revascularized coronary artery disease
  3. Concurrent acute coronary syndrome
  4. Age < 18 years-old
  5. History of significant ventricular arrhythmia without an ICD

Study details

Heart Failure, Cardiogenic Shock

NCT05700617

University of Chicago

30 April 2025

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.